prevacid medicaid reimbursement
BOSTON July 15, 2008– Attorney General Martha Coakley’s Office has entered into an agreement with international pharmaceutical manufacturer Bristol-Myers Squibb Company (BMS) to settle a variety of allegations of improper sales, marketing and price reporting practices. Under the terms of the settlement, BMS will pay $9,214,659. 43 to the Massachusetts Medicaid Program. “The Massachusetts Medicaid program expects health care providers, both large and small, to operate with honesty and integrity,” Attorney General Martha Coakley said. “Our office will continue to work in collaboration with our partners in state and federal law enforcement to identify and eliminate fraudulent marketing and pricing schemes that drain taxpayer dollars from an already overburdened health care system.” The agreement is the result of a four-part, seven-year investigation that began in 2001, and was coordinated with the federal government and other state Attorneys General involving BMS and Apothecon, Inc., a former BMS subsidiary that produced and marketed generic pharmaceutical products. The claims addressed in the investigation arose from nine separate whistle-blower lawsuits filed in various jurisdictions around the country, and a voluntary disclosure by BMS of potential violations of state and federal anti-kickback laws. The joint investigation was conducted by the U. prevacid long term health effects prevacid penicillin reaction prevacid expiration prevacid patient assistance program